Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00327119
Status:
COMPLETED
Last Update Posted:
2009-09-14
First Post:
2006-05-16
Brief Title:
Phase 2 Study of ABX-EGF Panitumumab in Japanese Subjects With M-colorectal Cancer
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Phase 2 Multicenter Single Arm Clinical Trial of ABX EGF Panitumumab Monotherapy in Japanese Subjects With Metastatic Colorectal Cancer Who Developed Progressive Disease or Relapsed While on or After Prior Fluoropyrimidine Irinotecan and Oxaliplatin Chemotherapy
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to assess the effect of treatment with ABX-EGF on best overall objective response rate by modified RECIST confirmed complete or partial response in Japanese subjects with metastatic colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None